CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 7th Annual BIO Investor Forum Conference, at 3:45 p.m. local time (6:45 p.m. EDT) on October 30, 2008, at the Palace Hotel in San Francisco, California.
Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule inhibitor of the Hedgehog pathway that is currently in Phase II clinical testing under collaboration with Genentech. Mr. Passeri also will discuss CUDC-101, CUDC-305 and Curis' other targeted cancer programs, in addition to other corporate activities.
There will also be a corresponding webcast of the presentation, which can be accessed by visiting:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=
CRIS&item_id=1995924
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
Mr. Passeri is also participating on a conference panel entitled "Bullseye: Novel Targets in Oncology" at 5:00 p.m. local time on the same day.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
Source: Curis, Inc.